Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment

Leukemia and Lymphoma

Volumn 44, Issue 4, 2003, Pages 703-708

  Hamaki, Tamae ^a,b   Kami, Masahiro ^a,b   Igarashi, Masahiro ^a   Kusumi, Eiji ^a   Arase, Yasuji ^a   Ishibashi, Toru ^c   Shimamura, Kenji ^c   Miyakoshi, Shigesaburo ^a   Morinaga, Shin Ichi ^a   Takaue, Yoichi ^b   Hayashi, Masahiro ^a   Mutou, Yoshitomo ^a  

^a TORANOMON HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Adult T cell lymphoma; Advanced hepatic failure; Non myeloablative transplant; Stem cell transplant; T ALL

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLUDARABINE; LAMIVUDINE; OCTREOTIDE; PROSTAGLANDIN E1; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGUS VARICES; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER INJURY; LIVER VENOOCCLUSIVE DISEASE; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; TIME FACTORS; VIDARABINE;

EID: 0037375692     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000097096     Document Type: Article

References (21)

1. Tsukasaki, K., Ikeda, S., Murata, K., Maeda, T., Atogami, S., Sohda, H., et al. (1993) "Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma", Leuk. Res. 17(2), 157-166.
2. Shimoyama, M. (1991) "Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)", Br. J. Haematol. 79(3), 428-437.
3. Utsunomiya, A., Miyazaki, Y., Takatsuka, Y., Hanada, S., Uozumi, K., Yashiki, S., et al. (2001) "Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation", Bone Marrow Transplant. 27(1), 15-20.
4. Ide, T., Kumashiro, R., Hino, T., Murashima, S., Ogata, K., Koga, Y., et al. (2001) "Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine", Hepatol. Res. 21(1), 76-84.
5. Gluckman, E., Jolivet, I., Scrobohaci, M.L., Devergie, A., Traineau, R., Bourdeau-Esperou, H., et al. (1990) "Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation", Br. J. Haematol. 74(3), 277-281.
6. Cockcroft, D.W. and Gault, M.H. (1976) "Prediction of creatinine clearance from serum creatinine", Nephron 16(1), 31-41.
7. Bearman, S., Appelbaum, F.R., Buckner, C., et al. (1988) "Regimen-related toxicity in patients undergoing bone marrow transplantation", J. Clin. Oncol. 6, 1562-1568.
8. Kamihira, S., Atogami, S., Sohda, H., Momita, S., Yamada, Y. and Tomonaga, M. (1994) "Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia", Cancer 73(11), 2753-2758.
9. Tochino, Y., Iwata, T., Takamizawa, A. and Hamajima, Y. (1971) "Studies on relationship between antitumor activity and metabolism of cyclophosphamide". Proc 3rd Symp. on Drug Metabolism and Action, 1971, Fukuoka, Japan.
10. Kemena, A., Fernandez, M., Bauman, J., Keating, M. and Plunkett, W. (1991) "A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids", Clin. Chim. Acta 200(2-3), 95-106.
11. Strasser, S.I. and McDonald, G.B. (1999) "Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management", Blood 93(4), 1127-1136.
12. Xun, C.Q., McSweeney, P.A., Boeckh, M., Storb, R.F., Broudy, V.C. and Thompson, J.A. (1999) "Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis", Blood 94(9), 3273-3276.
13. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., et al. (1997) "Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy", Blood 89(12), 4531-4536.
14. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., et al. (2001) "Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects", Blood 97(11), 3390-3400.
15. Yagci, M., Sneak, G.T. and Haznedar, R. (2000) "Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia", Am. J. Hematol. 64(3), 233-234.
16. Silvestri, F., Ermacora, A., Sperotto, A., Patriarca, E, Zaja, F., Damiani, D., et al. (2000) "Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation", Br. J. Haematol. 108(2), 394-396.
17. Wagner, T. and Fenneberg, K. (1984) "Pharmacokinetics and bioavailability of cyclophosphamide from formulations", Arzneimittelforschung 34(3), 313-316.
18. Wagner, T., Heydrich, D., Jork, T., Voelcker, G. and Hohorst, H.J. (1981) "Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test", J. Cancer Res. Clin. Oncol. 100(1), 95-104.
19. Juma, F.D. (1984) "Effect of liver failure on the pharmacokinetics of cyclophosphamide", Eur. J. Clin. Pharmacol. 26(5), 591-593.
20. Mahadevan, A., Kanegaonkar, R. and Hoskin, P.J. (1997) "Third space sequestration increases toxicity of fludarabine-a case report", Acta Oncol. 36(4), 441.
21. Malspeis, L., Grever, M.R., Staubus, A.E. and Young, D. (1990) "Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate", Semin. Oncol. 17(5 Suppl. 8), 18-32.